Zentalis Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
ZNTL
CUSIP
98943L107
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 98943L107 since 12/18/2024, newest first.

Filer % of Class Filed
Walters Group 13G/A Amendment 5
18.8% 8/19/2026
Event 8/14/2026
Barclays PLC 13G/A Amendment 1 3.2% 8/13/2026
Event 6/30/2026
BlackRock, Inc. 13G 5.2% 7/30/2026
Event 6/30/2026
Squadron Capital Management LLC 13G
5.1% 3/3/2026
Event 2/24/2026
Walters Group 13G/A Amendment 4
19.7% 1/5/2026
Event 12/31/2025
Matrix Capital Management Company, LP 13D/A Amendment 3
0% 1/2/2026
Event 12/30/2025
5AM Opportunities II (GP), LLC 13G
6.4% 12/30/2025
Event 12/18/2025
Matrix Capital Management Company, LP 13D/A Amendment 2
10.0% 12/15/2025
Event 12/15/2025
Barclays PLC 13G 5.3% 11/12/2025
Event 9/30/2025
Millennium Management LLC 13G/A Amendment 1
1.3% 10/14/2025
Event 9/30/2025
BlackRock, Inc. 13G/A Amendment 4 2.2% 7/16/2025
Event 6/30/2025
Eventide Asset Management, LLC 13G/A Amendment 4
0% 5/14/2025
Event 3/31/2025
Eventide Asset Management, LLC 13G/A Amendment 4
0% 5/13/2025
Event 3/31/2025
Eventide Asset Management, LLC 13G/A Amendment 3
6.3% 2/14/2025
Event 12/31/2024
Millennium Management LLC 13G
5.3% 2/4/2025
Event 1/29/2025
Walters William T 13G/A Amendment 3
9.9% 1/31/2025
Event 1/29/2025
Vanguard Group Inc 13G/A Amendment 6 4.6% 1/31/2025
Event 12/31/2024
Walters William T 13G/A Amendment 2
9.1% 1/22/2025
Event 1/21/2025
Walters William T 13G/A Amendment 1
7.0% 1/8/2025
Event 1/8/2025
Walters William T 13G
5.6% 12/10/2024
Event 12/3/2024
FMR LLC 13G/A Amendment 6
0.2% 12/6/2024
Event 11/29/2024

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 3 11.0 k $30.5 k
2026 Q2 121 47.4 M $230 M
2026 Q1 106 43.6 M $102 M
2025 Q4 88 40.7 M $55.0 M
2025 Q3 103 54.0 M $81.5 M
2025 Q2 120 56.8 M $65.9 M
2025 Q1 137 58.5 M $93.0 M
2024 Q4 148 64.4 M $195 M
2024 Q3 143 71.5 M $263 M
2024 Q2 151 79.1 M $324 M
2024 Q1 149 87.4 M $1.38 B
2023 Q4 130 82.1 M $1.24 B
2023 Q3 144 80.2 M $1.61 B
2023 Q2 141 82.5 M $2.32 B
2023 Q1 113 67.0 M $1.15 B
2022 Q4 112 67.4 M $1.36 B
2022 Q3 127 59.1 M $1.28 B
2022 Q2 126 58.5 M $1.64 B
2022 Q1 139 44.6 M $2.06 B
2021 Q4 149 43.5 M $3.65 B
2021 Q3 127 41.3 M $2.75 B
2021 Q2 129 40.2 M $2.14 B
2021 Q1 96 36.3 M $1.58 B
2020 Q4 109 37.3 M $1.94 B
2020 Q3 67 32.1 M $1.05 B
2020 Q2 63 27.0 M $1.29 B